Chenbo Zeng, a research assistant professor of radiology in the Perelman School of Medicine at the University of Pennsylvania, received an award from The National Comprehensive Cancer Network Oncology Research Program to further study abemaciclib, a drug used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Dr. Zeng’s project will use PET imaging of cell cycle arrest to predict responses to abemaciclib alone or in combination with endocrine therapy. Research funding is being provided by a grant from American pharmaceutical company Eli Lilly and Company.